CD34(+) cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies

The combination of fludarabine and melphalan as a reduced-intensity conditioning (RIC) regimen extends allogeneic hematopoietic SCT (HSCT) as a therapeutic option for elderly or frail patients with relapsed, refractory or other high-risk hematologic malignancies. Whether any modifiable factors exist...

Descripción completa

Detalles Bibliográficos
Autores principales: Holtan, S G, Hogan, W J, Elliott, M A, Ansell, S M, Inwards, D J, Porrata, L F, Johnston, P B, Micallef, I N, Lacy, M Q, Gastineau, D A, Litzow, M R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2010
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091776/
https://www.ncbi.nlm.nih.gov/pubmed/20208572
http://dx.doi.org/10.1038/bmt.2010.49

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091776/
https://www.ncbi.nlm.nih.gov/pubmed/20208572
http://dx.doi.org/10.1038/bmt.2010.49

Ejemplares similares